The influence of absorption enhancers on intranasal insulin absorption in normal and diabetic subjects

Journal of Controlled Release

Volumn 41, Issue 1-2, 1996, Pages 69-75

  Merkus, Frans W H M ^a   Schipper, Nicolaas G M ^a   Verhoef, J Coos ^a  

^a LEIDEN UNIVERSITY   (Netherlands)

Author keywords

Absorption enhancers; Efficacy; Insulin; Nasal delivery; Safety

Indexed keywords

BILE SALT; CYCLODEXTRIN; DEOXYCHOLATE SODIUM; DIDECANOYLPHOSPHATIDYLCHOLINE; GLYCOCHOLATE SODIUM; INSULIN; PENETRATION ENHANCING AGENT; POLIDOCANOL; TAURODIHYDROFUSIDATE; UNCLASSIFIED DRUG;

CILIARY MOTILITY; CLINICAL TRIAL; CONFERENCE PAPER; DIABETES MELLITUS; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; FREEZE DRYING; HUMAN; INTRANASAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LACRIMATION; MORPHOLOGY; NONHUMAN; NOSE INJURY; NOSE IRRITATION; NOSE MUCOSA; PRIORITY JOURNAL; PRURITUS; RABBIT; RAT; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0030222269     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/0168-3659(96)01357-0     Document Type: Conference Paper

References (31)

1. [1] L. Illum and S.S. Davis, Intranasal insulin: clinical pharmacokinetics, Clin. Pharmacokinet. 23 (1992) 30-41.
2. [2] S. Gizurarson and E. Bechgaard, Intranasal administration of insulin to humans, Diabetes Res. Clin. Pract. 12 (1991) 71-84.
3. [3] G.S. Gordon, A.C. Moses, R.D. Silver, J.S. Flier and M.C. Carey, Nasal absorption of insulin: enhancement by hydrophobic bile salts, Proc. Natl. Acad. Sci. USA 82 (1985) 7419-7423.
4. [4] A.E. Pontiroli, M. Alberetto, A. Secchi, G. Dossi, I. Bosi and G. Pozza, Insulin given intranasally induces hypoglycaemia in normal and diabetic subjects, Br. Med. J. 284 (1982) 303-306.
5. [5] A.E. Pontiroli, M. Alberetto, E. Pajetta, A. Calderara and G. Pozza, Human insulin plus sodium glycocholate in a nasal spray formulation: improved bioavailability and effectiveness in normal subjects, Diab. Metab. 13 (1987) 441-443.
6. [6] A.C. Moses, G.S. Gordon, M.C. Carey and J.S. Flier, Insulin administered intranasally as an insulin-bile salt aerosol: effectiveness and reproducibility in normal and diabetic subjects, Diabetes 32 (1983) 1040-1047.
7. [7] A.G. Frauman, M.E. Cooper, B.J. Parsons, G. Jerums and W.J. Louis, Long-term use of intranasal insulin in insulin-dependent diabetic patients, Diabetes Care 10 (1987) 573-578.
8. [8] I.R. Sinay, S. Sclimovich, S. Damilano, A.L. Cagide, M.C. Faingold, E.B. Facco, M.S. Gurfinkel and P. Arias, Insulin administration in insulin dependent diabetes: reproducibility of its absorption and effects, Horm. Metab. Res. 22 (1990) 307-308.
9. [9] M. El-Etr, G. Slama and N. Desplanque, Preprandial intranasal insulin as adjuvant therapy in type 2 diabetics. Lancet II (1987) 1085-1086.
10. [10] D.G. Bruce, D.J. Chisholm, L.H. Stoelien, M. Borkman and E.W. Kraegen, Meal-time intranasal insulin delivery in type II diabetes, Diabetic Med. 8 (1991) 366-370.
11. [11] A.G. Frauman, G. Jerums and W.J. Louis, Effects of intranasal insulin in nonobese type II diabetes, Diabetes Res. Clin. Pract. 3 (1987) 197-202.
12. [12] A.G. Frauman, R. Buchanan, G. Jerums and W.J. Louis, Intranasal insulin (INI) treatment of type I diabetes: clinical and immunological effects using two different absorption enhancing adjuvants, Diabetes Res. Clin. Pract. 5 (Suppl. 1) (1988) 5162.
13. [13] R. Salzman, J.E. Manson, G.T. Griffing, R. Kimmerle, N. Ruderman, A. McCall, E.J. Stoltz, C. Mullin, S. Small, J. Armstrong and J.C. Melby, Intranasal aerosolized insulin, N. Engl. J. Med. 312 (1985) 1078-1084.
14. [14] A.C. Moses, Nasal absorption of insulin, Pharm. Weekbl. Sci. Ed. 10 (1988) 45-46.
15. [15] M.S. Nolte, C. Taboga, E. Salamon, A. Moses, J. Longenecker, J. Flier and J.H. Karam, Biological activity of nasally administered insulin in normal subjects, Horm. Metab. Res. 22 (1990) 170-174.
16. [16] C.H. Binder, T. Lawritzen and O. Faber, Insulin pharmacokinetics, Diabetes Care 7 (1984) 188-199.
17. [17] K. Drejer, A. Vaag, K. Bech, P. Hansen, A.R. Sørensen and N. Mygind, Intranasal administration of insulin with phospholipids as absorption enhancer: pharmacokinetics in normal subjects, Diabetic Med. 9 (1992) 335-340.
18. [18] M.A.J.M. Jacobs, R.H. Schreuder, K. Jap-A-Joe, J.J. Nauta, P.M. Andersen and R.J. Heine, The pharmacodynamics and activity of intranasally administered insulin in healthy male volunteers, Diabetes 42 (1993) 1649-1655.
19. [19] J. Hilsted, S. Madsbad, A. Hvidberg, M.H. Rasmussen, T. Krarup, H. Ipsen, B. Hansen, M. Pedersen, R. Djurup and B. Oxenbøll, Intranasal insulin therapy: the clinical realities, Diabetologia 38 (1995) 680-684.
20. [20] S. Hirai, H. Okada, T. Yashjid and Y. Uda, Pharmaceutical composition and its use, European Patent Application 883302118.1, November 16, 1983.
21. [21] F.W.H.M. Merkus, J.C. Verhoef, S.G. Romeijn and N.G.M. Schipper, Absorption enhancing effect of cyclodextrins on intranasally administered insulin in rats, Pharm. Res. 8 (1991) 588-592.
22. [22] N.G.M. Schipper, S.G. Romeijn, J.C. Verhoef and F.W.H.M. Merkus, Nasal insulin delivery with dimethyl-β-cyclodextrin as an absorption enhancer in rabbits: powder more effective than liquid formulations, Pharm. Res. 10 (1993) 682-686.
23. [23] F.W.H.M. Merkus, N.G.M. Schipper, J. Verhoef, R. Bianchi, E. Helmich-Teuben and D.W. Erkelens, Intranasal insulin absorption in volunteers and diabetes mellitus patients, Thérapie 50 (1995) Suppl. 1, Abstract No. 401.
24. [24] E.W.T.M. ter Braak, R. Bianchi and D.W. Erkelens, Faster, shorter and more profound action of Lys(B28) Pro(B29) human insulin analogue compared to regular insulin irrespective of the injection site, Diabetes 42 (1993) 207A.
25. [25] J.A. Galloway and R.E. Chance, Approaches to insulin analogues, Diabetes Annu. 8 (1994) 277-297.
26. [26] Z. Shao, R. Krishnamoorthy and A.K. Mitra, Cyclodextrins as nasal absorption promoters of insulin: mechanistic evaluations, Pharm. Res. 9 (1992) 1157-1163.
27. [27] F.W.H.M. Merkus, N.G.M. Schipper, W.A.J.J. Hermans, S.G. Romeijn and J.C. Verhoef, Absorption enhancers in nasal drug delivery: efficacy and safety, J. Control. Rel. 24 (1993) 201-208.
28. [28] E. Marttin, J.C. Verhoef, S.G. Romeijn and F.W.H.M. Merkus, Effects of absorption enhancers on rat nasal epithelium in vivo: release of marker compounds in the nasal cavity, Pharm. Res. 12 (1995) 1151-1157.
29. [29] K. Albertsson-Wikland, L. Hedin, P. Jansson, S. Rosberg and C. Wikström, Intranasal delivery of human growth hormone: optimization of formulation, Drug Dev. Res. 34 (1995) 353-360.
30. [30] T. Kissel, J. Drewe, S. Bantle, A. Rummelt and C. Beglinger, Tolerability and absorption enhancement of intranasally administered octreotide by sodium taurodihydrofusidate in healthy subjects, Pharm. Res. 9 (1992) 52-57.
31. [31] T. Irie, K. Wakamatsu, H. Arima, H. Aritomi and K. Uekama, Enhancing effects of cyclodextrins on nasal absorption of insulin in rats, Int. J. Pharm. 84 (1992) 129-139.